50岁以上处方及非法阿片类中毒的纳洛酮治疗:2015-2020年全国毒物数据系统分析
该研究分析2015-2020年全国毒物数据系统中83,135例50岁以上阿片类中毒病例,采用单变量和多变量逻辑回归评估纳洛酮给药的相关因素。处方阿片中毒病例接受纳洛酮的比例从21.9%稳步升至28.4%,非法阿片中毒病例从51.9%升至59.8%(2019年最高64.4%)。2020年非法阿片中毒未用纳洛酮者死亡率为31.4%,用者为2.3%。在医疗机构管理的病例接受纳洛酮的比值更高;处方阿片中毒中老年、女性及非医疗机构管理病例的纳洛酮使用率尤其低。结论提示需增加纳洛酮共同处方和获取途径。
要点
- 50岁以上处方阿片中毒病例纳洛酮使用率从2015年21.9%升至2020年28.4%,整体仍低。
- 2020年非法阿片中毒未用纳洛酮者死亡率31.4%,用纳洛酮者仅2.3%。
- 处方阿片中毒中老年、女性及非医疗机构管理病例纳洛酮使用率尤其低,即使主要医疗结局也如此。
- 涉及羟考酮、吗啡、美沙酮、处方芬太尼、氢吗啡酮、羟吗啡酮及其他/未知阿片的病例接受纳洛酮的比值更高。
- 在医疗机构管理的病例接受纳洛酮治疗的比值高于非医疗机构。
适用人群与场景
- 2015-2020年全国毒物数据系统中50岁及以上、涉及阿片类中毒的83,135例病例。
- 包括处方阿片和非法阿片中毒病例;原文未明确排除标准。
诊断标准与关键阈值
- 原文未提及
处置流程与药物剂量
- 原文未提及
红旗征与不能漏的情况
- 非法阿片中毒未接受纳洛酮治疗者2020年死亡率达31.4%,需紧急识别并处理。
- 处方阿片中毒中老年、女性及非医疗机构管理病例纳洛酮使用率尤其低,即使主要医疗结局也低,需警惕遗漏。
研究设计与关键结果
- 研究类型为对2015-2020年全国毒物数据系统83,135例50岁以上阿片类中毒病例的回顾性分析,采用单变量和多变量逻辑回归。
- 处方阿片中毒病例接受纳洛酮的比例从2015年21.9%升至2020年28.4%。
- 非法阿片中毒病例接受纳洛酮的比例2015年51.9%、2020年59.8%,2019年最高64.4%。
- 2020年非法阿片中毒未用纳洛酮治疗者死亡率为31.4%,用纳洛酮治疗者为2.3%。
- 医疗机构管理病例接受纳洛酮治疗的比值更高;处方阿片中毒中老年、女性及非医疗机构管理病例纳洛酮使用率尤其低。
- 涉及羟考酮、吗啡、美沙酮、处方芬太尼、氢吗啡酮、羟吗啡酮及其他/未知阿片的病例纳洛酮给药比值更高。
证据类型、等级与局限
- 证据类型为基于全国毒物数据系统的回顾性数据库分析;原文未提供证据等级或推荐强度。
- 局限性:原文未明确说明,但设计本身为回顾性、观察性数据分析。
对床旁实践的改变
- 提示需增加纳洛酮共同处方及其他便利获取途径,以预防使用处方阿片的老年人中毒死亡。
- 对50岁以上处方阿片中毒病例,尤其老年、女性及非医疗机构管理场景,应警惕纳洛酮使用不足。
- 非法阿片中毒病例纳洛酮使用率虽较高,但2020年下降且未用者死亡率高,强调获取该救命干预的重要性。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
CONTEXT: Older adults are less likely than younger adults to receive naloxone therapy. Given high rates of prescription opioid use/misuse and increasing illicit opioid use among older adults, factors associated with naloxone administration for older opioid poisoning cases need examination.
METHODS: We analyzed the 83,135 opioid-involved cases aged 50+ from the 2015-2020 National Poison Data System. Single-variable logistic regression was used to examine associations of naloxone administration with demographic factors, exposure site/reason, medical outcomes, management site/level of care, clinical effects, and other interventions. Multivariable logistic regression models were fit to examine associations of naloxone administration with different types of opioids.
RESULTS: Over the six years, the proportion of prescription opioid cases that received naloxone therapy increased steadily from 21.9% to 28.4%. The proportion of illicit opioid cases that received naloxone therapy was 51.9% in 2015 and 59.8% in 2020 with a high of 64.4% in 2019. In 2020, the death rate for illicit opioid cases without naloxone therapy was 31.4% compared to 2.3% for those with the therapy. Cases managed at healthcare facilities (HCF) had higher odds of receiving naloxone therapy. Among prescription opioid cases, naloxone therapy rates among older and female cases and those managed at non-HCF settings were especially low even for major medical outcomes. Cases involving oxycodone, morphine, methadone, prescription fentanyl, hydromorphone, oxymorphone, and other/unknown opioids had higher odds of naloxone administration.
DISCUSSION: Rates of naloxone therapy for older prescription opioid poisoning cases need improvement. While rates were higher among illicit opioid cases, the drop in 2020 and the sharp increase in deaths among illicit opioid cases without naloxone therapy confirm the importance of access to this life-saving intervention.
CONCLUSIONS: Increased naloxone co-prescribing and other means of facilitating access to naloxone are needed to prevent opioid poisoning deaths among older adults who use prescription opioids.
参考来源
- Choi NG, Choi BY, DiNitto DM, et al. Naloxone therapy for prescription and illicit opioid poisoning cases aged 50 + in the national poison data system, 2015-2020. Clin Toxicol (Phila). 2021. PMID: 34554013. doi:10.1080/15563650.2021.1981362
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。